Sorrento Therapeutics, Inc.

( )
SRNE After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. -0.35%62.981.0%$410.78m
AMGNAmgen, Inc. 0.41%241.491.3%$404.45m
BIIBBiogen, Inc. -0.22%285.501.4%$345.61m
ILMNIllumina, Inc. -0.38%324.723.5%$314.55m
VRTXVertex Pharmaceuticals, Inc. 0.14%235.831.9%$273.15m
REGNRegeneron Pharmaceuticals, Inc. 0.10%385.942.6%$211.56m
EXASEXACT Sciences Corp. -1.92%88.0624.0%$200.81m
ITCIIntra-Cellular Therapies, Inc. -1.43%26.259.0%$186.59m
ALXNAlexion Pharmaceuticals, Inc. 0.68%113.272.0%$174.71m
INCYIncyte Corp. -0.15%80.502.5%$140.53m
SRPTSarepta Therapeutics, Inc. -1.84%127.9014.6%$135.49m
AAgilent Technologies, Inc. 0.79%90.171.6%$114.69m
BMRNBioMarin Pharmaceutical, Inc. -0.97%88.274.3%$106.23m
BLUEbluebird bio, Inc. 0.59%98.0414.2%$94.93m
SGENSeattle Genetics, Inc. 1.25%109.006.1%$89.92m

Company Profile

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.